ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
FR Fritzsche, M Jung, A Tölle, P Wild, A Hartmann… - European urology, 2008 - Elsevier
FR Fritzsche, M Jung, A Tölle, P Wild, A Hartmann, K Wassermann, A Rabien, M Lein…
European urology, 2008•ElsevierOBJECTIVES: Adisintegrin and metalloprotease (ADAM) 9 has been implicated in tumour
progression of prostate cancer. We evaluated the expression of ADAM9 on protein and
messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following
prostatectomy and correlated the findings with clinicopathological parameters including
prostate-specific antigen (PSA) relapse times. METHODS: We immunostained 198
clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional …
progression of prostate cancer. We evaluated the expression of ADAM9 on protein and
messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following
prostatectomy and correlated the findings with clinicopathological parameters including
prostate-specific antigen (PSA) relapse times. METHODS: We immunostained 198
clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional …
OBJECTIVES
Adisintegrin and metalloprotease (ADAM) 9 has been implicated in tumour progression of prostate cancer. We evaluated the expression of ADAM9 on protein and messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following prostatectomy and correlated the findings with clinicopathological parameters including prostate-specific antigen (PSA) relapse times.
METHODS
We immunostained 198 clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analysed via quantitative reverse transcriptase-polymerase chain reaction.
RESULTS
ADAM9 was significantly upregulated in prostate cancer compared with normal tissue on mRNA and protein level. ADAM9 protein expression was significantly associated with shortened PSA relapse–free survival in univariate and multivariate analyses, particularly in patients who had received prior androgen ablation.
CONCLUSIONS
ADAM9 is overexpressed in prostate cancer cases and is an independent prognostic marker of PSA relapse–free survival following radical prostatectomy. Further studies are needed to verify its role as a predictive marker of response to androgen ablation.
Elsevier